CN101057862A - Medicinal composition for treating senile osteoarthropathy - Google Patents
Medicinal composition for treating senile osteoarthropathy Download PDFInfo
- Publication number
- CN101057862A CN101057862A CN 200710105249 CN200710105249A CN101057862A CN 101057862 A CN101057862 A CN 101057862A CN 200710105249 CN200710105249 CN 200710105249 CN 200710105249 A CN200710105249 A CN 200710105249A CN 101057862 A CN101057862 A CN 101057862A
- Authority
- CN
- China
- Prior art keywords
- calcium
- hydrogen phosphate
- pharmaceutical composition
- calcium hydrogen
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a medicine compound, comprising medical active components of chondroitin sulfate, hydrochloric acid aminoglucose, calcium hydrogen orthophosphate and medical acceptable findings. The consumption of hydrochloric acid aminoglucose is 125-1500mg in every dosage agent, chondroitin sulfate is 100-1200mg, and calcium hydrogen orthophosphate is 40-500mg (calculated by calcium). The invention can not only prevent and treat senile ostarthritis, but also replenish the calcium and phosphorus, and the absorption is good, and will not cause side effect such as calcemia or calcium toxic because of high calcium concentration.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of preventing and treating senile osteoarthritis, relate in particular to the pharmaceutical composition that a kind of glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate are formed.
Background technology
Osteoarthritis is a modal joint disease among the old people, and osteoarthritis also claims degenerative osteoarthritis, hyperosteogeny, and common sympton increases the weight of for the arthralgia of getting involved, activity, and the back of having a rest is alleviated, inertia has stiff sense etc. for a long time.China has entered the ranks of world aged country, and the aged of Pekinese has reached 13%, thereby the incidence rate of Senile disease also rises gradually.Investigate abroad below 25 years old that sickness rate generally is no more than 5% among the crowd, but owned by everyone more than 90% in 80 years old crowd.
With the age increase, each physiological system of the motor system and other of human body is the same, and it is aging that physiological takes place.Form because bone absorption surpasses sclerotin, bone density reduces, easily cause osteoporosis and easily fracture, especially the female old aged people people after menopause owing to the easier generation osteoporosis of change of hormone in vivo level.The old people is with the growth at age, and bone weight alleviates, from 50-80 year, and every increase by 10 years old, the bone weight male alleviates 5%, and the women alleviates 7%.Degeneration often takes place in articular cartilage, water content and hydrophilic mucopolysaccharide reduce, chrondroitin reduces, group crowd 90%X line was observed the cartilage degeneration phenomenon is arranged in 40 years old, the regression of old people's articular cartilage is particularly evident, sometimes articular cartilage can all be degenerated, and two ends, joint surface of bone directly contacts and causes severe pain when movable.This shows that osteoporosis and cartilage degradation are two main causes that senile osteoarthritis takes place.Though osteoarthritis and osteoporotic relation are at present still undetermined; but for the old people; osteoporosis and osteoarthritis are simultaneous often; ADL to elderly patients has caused adverse influence, therefore prevents and treats osteoporosis in the treatment osteoarthritis and has certain clinical meaning.
The traditional treatment medicine of osteoarthritis is a NSAID (non-steroidal anti-inflammatory drug), and this class medicine life-time service has bigger gastrointestinal side effect, and therefore clinical use is restricted.At present the class symptom/disease adjustment type Etodolac of research such as glucosamine and chondroitin sulfate etc. have better curative effect aspect articular cartilage and the anti-inflammatory and antalgic improving, and untoward reaction simultaneously is less.
Because the osteoarthritis pathogenesis is also unclear, causes to have certain difficulty in the treatment.But osteoarthritis is in its pathological change, and the biosynthesis obstacle that constitutes the main component poly-glucosamine of chrondroitin substrate is clearly.The early stage viewed hypermetabolism state of arthritis is the feedback of chondrocyte to the damage of proteoglycan cartilage structure.Under these states, finally can cause the cartilage injury, because " the super metabolism " of stress-induced reaction mainly is the regression of catabolism chain reaction and cartilage form.The regression of cartilage is progressive, and can be continued extraordinary and/or unusually stress institute's facilitation.If early stage " super metabolism " reaction of arthritis is the reaction of counteracting environmental stress a kind of protectiveness or that do not have effect, those medicines of strengthening anabolism and minimizing catabolic reaction can delay the regression of cartilage so.Natural drug with this ability is called as biological response modifier (BRM), comprises derivant such as protein, polysaccharide and the glucose of those natural drugs.The definition of such medicine infer these medicines can improve the host to multiple stress defense reaction.Studies show that symptom/disease adjustment type Etodolac (S/DMOADS) glucosamine and chondroitin sulfate are the medicines that belongs to this class.In a rabbit instability arthritis model research, from diet, give the degeneration that glucosamine and chondroitin sulfate can be protected the cartilage form and the cartilage that slows down.In these animals, normal humerus cartilage does not change, and its curative effect derives from the effect of medicine to chondrocyte in stress the joint.In another research, injected the chymopapain animal and can improve proteoglycan content in stress cartilage, but normal structure has not been had influence with glucosamine.A correlational study shows that chondroitin sulfate gives to significantly improve the proteoglycan content at injection of joint position before or after injection of chymopapain.
Chinese patent application 200610057274.X discloses the Pharmaceutical composition of a kind of glucosamine hydrochloride and chondroitin sulfate composition, is used for the treatment of the arthritis at each position of whole body.
Maybe may to suffer from arthritic crowd also mostly are older crowds owing to suffer from arthritis, and with the loss of calcium, also there is deficiency in the absorbtivity of calcium usually for they; And the disappearance of calcium can be aggravated the damage in joint, add calcium important assosting effect is played in treatment and prevention arthritis, in the nutrition reparation of joint, carry out an amount of replenishing the calcium and to delay losing of sclerotin to a certain extent, have the effect of strengthening joint repair nutrition.
Chinese patent application 200310113747.X discloses a kind of pharmaceutical composition of the treatment of arthritis of being made up of D-glucosamine, chrondroitin and calcium source, wherein D-glucosamine is a kind of, two or more the combination in D-glucosamine monomer, D-glucosamine hydrochlorate and the D-glucosamine sulfate, a kind of, two or more combination in preferably sulfuric acid D-glucosamine monomer, sulphuric acid D-glucosamine potassium salt and the sulphuric acid D-glucosamine sodium salt, the best is a D-glucosamine sulphuric acid potassium salt; Chrondroitin is the various chrondroitins that meet the countries concerned's standard or industry standard, as chondroitin sulfate etc.; The calcium source is calcium gluconate, calcium lactate or calcium carbonate.For the sulphuric acid D-glucosamine, the part of onset only is a glucosamine, and has many shortcomings as a kind of medicine, draws wet, its amino very easily oxidation stain as sulphuric acid D-glucosamine height; For the calcium source, the Wu Jing of health education section of Beijing Friendship Hospital is entitled as at one piece in the report of " how science is replenished the calcium " and writes " calcium carbonate, calcium lactate, calcium gluconate; its absorbance is 30%-80% ", as seen the calcium source in the above-mentioned patent application absorbs and is bad, and meeting such as calcium gluconate, calcium lactate produces some side effect because of blood calcium concentration is too high, therefore as hypercalcemia syndrome or calcium intoxication, the curative effect of the pharmaceutical composition of forming with above-mentioned calcium source and D-glucosamine, chrondroitin can not be satisfactory.
The inventor is surprised to find that in the compound recipe of development glucosamine, chondroitin sulfate and calcium and adopts calcium hydrogen phosphate can replenish calcium required in the skeleton better that the ratio of calcium and phosphorus is 4: 3 in the calcium hydrogen phosphate, has also replenished phosphorus when replenishing calcium.Calcium and phosphorus are the key components of bone mineral in the skeleton, and the content of calcium is 99.3% in the bone mineral, and the content of phosphorus is 86.0%, and bone mineral prevents that to strengthening bone hardness osteoporosis from playing an important role.The proper ratio of calcium and phosphorus also is that absorption of human body calcium is necessary, the ratio of calcium and phosphorus that studies show that helped the absorption of calcium most at 1: 1～3: 2 o'clock, and the ratio of calcium in the calcium hydrogen phosphate and phosphorus just in time drops in this scope, and calcium hydrogen phosphate can not cause the side effect that produces because of blood calcium concentration is too high such as calcium gluconate, calcium lactate etc. simultaneously.
Summary of the invention
The invention provides a kind of pharmaceutical composition of preventing and treating senile osteoarthritis, comprise glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate and acceptable accessories as active component.
The preferred nanometer calcium hydrogen phosphate of calcium hydrogen phosphate among the present invention, the nanometer calcium hydrogen phosphate is easier to be absorbed by body.
Nanometer calcium hydrogen phosphate among the present invention is an existing nanometer calcium hydrogen phosphate in the prior art, as the nanometer calcium hydrogen phosphate that utilizes phosphorous 12.85, the calcic 16.16% that calcium hydrophosphate fodder makes through the gelatin complex coacervation that is provided by the micro-nano academy of Shanghai Communications University.
The pharmaceutical composition of the senile osteoarthritis of control provided by the present invention, can prevent and treat senile osteoarthritis well, and in the treatment osteoarthritis, replenish the calcium that runs off, when replenishing the calcium, replenish phosphorus, add bone strengthening calcium and form, strengthen skeleton, improve bone density, strengthen the bone holding capacity, to improving old bone holding capacity and the therapeutic effect of senile osteoarthritis being better than single any active compound of using.
Among the present invention; glucosamine hydrochloride and chondroitin sulfate play collaborative potentiation to osteoarticular protection, reparation and articular cartilage; calcium hydrogen phosphate has facilitation to the growth promoter and the bone density of bone; and when replenishing the calcium phosphorus supplement; adding bone strengthening calcium forms; strengthen skeleton, the utilization that can be absorbed by the body preferably simultaneously can not cause the side effect that produces because of blood calcium concentration is too high such as calcium gluconate, calcium lactate etc.Glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate three share, and can prevent and treat the osteoarthrosis inflammation, again can bone density improving, strengthen skeleton, and improve immunity, absorb better simultaneously.
In the prior art, prevent and treat the pharmaceutical composition of osteoarthritis and form by glucosamine hydrochloride and chondroitin sulfate usually, also increase the calcium source simultaneously and replenish a certain amount of calcium.But calcium source used in the prior art is generally calcium lactate, calcium gluconate or calcium carbonate, but these calcium sources all exist absorb bad, thereby and can cause the too high defective that causes hypercalcemia syndrome or calcium intoxication of blood calcium concentration after taking.Among the present invention, adopting calcium hydrogen phosphate and glucosamine hydrochloride and chondroitin sulfate is active constituents of medicine, form the pharmaceutical composition that prevents and treat senile osteoarthritis with acceptable accessories, calcium hydrogen phosphate can be when replenishing the calcium phosphorus supplement, adding bone strengthening calcium forms, strengthen skeleton, the utilization that can be absorbed by the body preferably simultaneously can not cause the side effect that produces because of blood calcium concentration is too high such as calcium gluconate, calcium lactate etc.The preferred nanometer calcium hydrogen phosphate of calcium hydrogen phosphate among the present invention, the easier utilization that is absorbed by the body.
The pharmaceutical composition of the senile osteoarthritis of control provided by the present invention, comprise glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate and acceptable accessories as active component, the consumption of the glucosamine hydrochloride described in wherein every preparation unit is that the consumption of 125-1500mg, chondroitin sulfate is that the consumption of 100-1200mg, calcium hydrogen phosphate is counted 40-500mg with calcium.
Preferably, the consumption of glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate is respectively in every preparation unit:
Glucosamine hydrochloride 150-750mg
Chondroitin sulfate 150-600mg
Calcium hydrogen phosphate (in calcium) 150-300mg.
Best, the consumption of glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate is respectively in every preparation unit:
Glucosamine hydrochloride 375mg
Chondroitin sulfate 300mg
Calcium hydrogen phosphate (in calcium) 200mg.
The preferred nanometer calcium hydrogen phosphate of above-mentioned calcium hydrogen phosphate is because the easier utilization that is absorbed by the body of nanometer calcium hydrogen phosphate.
Among the present invention, described acceptable accessories is filler, disintegrating agent, binding agent, lubricant.
Above-mentioned filler is mannitol or lactose, disintegrating agent is one or both in crospolyvinylpyrrolidone or the cross-linking sodium carboxymethyl cellulose, binding agent is ethanol or hydroxypropyl emthylcellulose, and lubricant is one or more in micropowder silica gel, magnesium stearate, Pulvis Talci, the PEG400.
The pharmaceutical composition of the senile osteoarthritis of control provided by the present invention, its dosage form are tablet, dispersant, chewable tablet, effervescent tablet, capsule or mix suspension grain.
Pharmaceutical composition of the present invention can adopt the formulation preparation technology of this area routine, the present composition is made different dosage forms, the oral formulations conventional as tablet, dispersant, chewable tablet, capsule or mix suspension grain etc., drug combination preparation of the present invention is preferably tablet, dispersant, chewable tablet or mix suspension grain, these dosage forms can adopt preparation technology's preparation of this area routine, preferably adopt preparation technology's preparation of the present invention.
In the tablet of the present invention, can be prepared into common tablet, but preferably it is prepared into coated tablet.Disintegrating agent is a crospolyvinylpyrrolidone in the additive of tablet, and binding agent is an ethanol, and lubricant is micropowder silica gel and hard magnesium, and coating partly is hydroxypropyl emthylcellulose, PEG400, Pulvis Talci and ethanol.Preparation method can adopt conventional method, but preferably adopts preparation technology of the present invention.
The preparation technology of tablet provided by the present invention is:
1) get three kinds of chondroitin sulfate as active constituents of medicine, glucosamine hydrochloride and calcium hydrogen phosphate in proportion and mix with the disintegrating agent of 1/2 recipe quantity, use alcohol granulation, sieve, dry granulate must be done granule;
2) add remaining disintegrating agent in above-mentioned dried granule, add mix lubricant again, tabletting gets the sheet heart;
3) with the Gonak of ethanol preparation 4%, add the PEG400 and the Pulvis Talci of recipe quantity, mix sieve coating material;
4) with step 2) the sheet heart of gained places coating pan, coating after the preheating, 30-40 ℃ of control coating temperature until coating weightening finish 2-3%, taken out coated tablet, and drying is up to the standards, packs and promptly gets tablet of the present invention.
The preferred nanometer calcium hydrogen phosphate of above-mentioned calcium hydrogen phosphate.
In the chewable tablet of the present invention, filler is a mannitol, and binding agent is an ethanol, and lubricant is micropowder silica gel and magnesium stearate, and chewable tablet of the present invention can adopt preparation technology's preparation of conventional tablet.
In the dispersible tablet of the present invention, disintegrating agent is crospolyvinylpyrrolidone and cross-linking sodium carboxymethyl cellulose, and binding agent is an ethanol, and lubricant is micropowder silica gel and magnesium stearate.Preparation method can adopt conventional preparation method, preferably adopts preparation technology provided by the present invention, and promptly crospolyvinylpyrrolidone and cross-linking sodium carboxymethyl cellulose adopt inside and outside addition.
In the mix suspension grain agent of the present invention, filler is a lactose, and binding agent is an ethanol, and lubricant is micropowder silica gel.Preparation method can adopt conventional preparation method, preferably adopts preparation technology provided by the present invention, promptly gets chondroitin sulfate, glucosamine hydrochloride, calcium hydrogen phosphate and lactose and mixes, use alcohol granulation, sieve, dry, granulate, add micropowder silica gel, mix the back pack promptly.
The preferred nanometer calcium hydrogen phosphate of above-mentioned calcium hydrogen phosphate.
The pharmaceutical composition of the senile osteoarthritis of control provided by the present invention not only can excellent prevention and the senile osteoarthritis of treatment, have no side effect, and compare its effect with prior art more outstanding, and glucosamine hydrochloride and chondroitin sulfate play collaborative potentiation to osteoarticular protection, reparation and articular cartilage; Calcium hydrogen phosphate has facilitation to the growth promoter and the bone density of bone, and when replenishing the calcium phosphorus supplement, adding bone strengthening calcium forms, strengthen skeleton, the utilization that can be absorbed by the body preferably simultaneously can not cause side effect such as the hypercalcemia syndrome that produces because of blood calcium concentration is too high such as calcium gluconate, calcium lactate etc. or calcium intoxication.The three share, and can prevent and treat the osteoarthrosis inflammation, again can bone density improving, strengthen skeleton, and improve immunity.And the preferred nanometer calcium hydrogen phosphate of the calcium hydrogen phosphate among the present invention, thereby make medicine of the present invention more help the absorption by human body utilization.
The specific embodiment
Following embodiment is in order to further describe the pharmaceutical composition of the senile osteoarthritis of control provided by the present invention, rather than restriction the present invention.
The tablet of [embodiment 1] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 375g
Chondroitin sulfate 300g
Calcium hydrogen phosphate (in calcium) 150g
Crospolyvinylpyrrolidone 50g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
The coating part:
Hydroxypropyl emthylcellulose (5cps) 16g
PEG400 4g
Pulvis Talci 4g
Ethanol 400ml
Coating weightening finish 2%～3%
Preparation method: get chondroitin sulfate, glucosamine hydrochloride, calcium hydrogen phosphate and 1/2 amount crospolyvinylpyrrolidone mix homogeneously, granulate in right amount with ethanol, made granule is crossed 40 mesh sieves, hot-air seasoning, granulate.Dried granule adds remaining crospolyvinylpyrrolidone, micropowder silica gel and magnesium stearate, and mix homogeneously is with the special-shaped stamping of ellipse.With the HPMC solution of ethanol preparation 4%, add the PEG400 and the Pulvis Talci of recipe quantity, it is standby to cross 100 mesh sieves behind the mix homogeneously.Plain sheet is placed coating pan, and 40 ℃ of preheatings began coating after 30 minutes, and 30～40 ℃ of control coating temperature are until coating weightening finish 2～3%.Take out coated tablet, 45 ℃ of dryings were inspected by ready samples after 5 hours, after the assay was approved packing.
The tablet of [embodiment 2] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 375g
Chondroitin sulfate 300g
Calcium hydrogen phosphate (in calcium) 430g
Crospolyvinylpyrrolidone 50g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
Coating part and preparation method are with embodiment 1.
The tablet of [embodiment 3] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 125g
Chondroitin sulfate 1200g
Calcium hydrogen phosphate (in calcium) 40g
Crospolyvinylpyrrolidone 50g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
Coating part and preparation method are with embodiment 1.
The tablet of [embodiment 4] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 1500g
Chondroitin sulfate 100g
Calcium hydrogen phosphate (in calcium) 40g
Crospolyvinylpyrrolidone 50g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
Coating part and preparation method are with embodiment 1.
The chewable tablet of [embodiment 5] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 375g
Chondroitin sulfate 300g
Calcium hydrogen phosphate (in calcium) 430g
Mannitol 500g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
Preparation method: get chondroitin sulfate, glucosamine hydrochloride, calcium hydrogen phosphate mix homogeneously, granulate in right amount with ethanol, made granule is crossed 40 mesh sieves, hot-air seasoning, granulate.Dried granule adds micropowder silica gel and magnesium stearate, and mix homogeneously is with round special-shaped stamping.
The dispersible tablet of [embodiment 6] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 375g
Chondroitin sulfate 300g
Calcium hydrogen phosphate (in calcium) 150g
Crospolyvinylpyrrolidone 100g
Cross-linking sodium carboxymethyl cellulose 100g
Ethanol is an amount of
Micropowder silica gel 10g
Magnesium stearate 10g
Make 1000
Preparation method: get chondroitin sulfate, glucosamine hydrochloride, calcium hydrogen phosphate, 1/2 crospolyvinylpyrrolidone and 1/2 cross-linking sodium carboxymethyl cellulose mix homogeneously, granulate in right amount with ethanol, made granule is crossed 40 mesh sieves, hot-air seasoning, granulate.Dried granule adds crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, micropowder silica gel and the magnesium stearate of surplus, and mix homogeneously is with the special-shaped stamping of ellipse.
The mix suspension grain agent of [embodiment 7] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 750g
Chondroitin sulfate 600g
Calcium hydrogen phosphate (in calcium) 200g
Lactose 2000g
Ethanol is an amount of
Micropowder silica gel 10g
Make 1000 bags
Preparation method: get chondroitin sulfate, glucosamine hydrochloride, calcium hydrogen phosphate and lactose mix homogeneously, granulate in right amount with ethanol, made granule is crossed 40 mesh sieves, hot-air seasoning, granulate.Dried granule adds micropowder silica gel, packs behind the mix homogeneously.
The mix suspension grain agent of [embodiment 8] glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate
Prescription:
Glucosamine hydrochloride 150g
Chondroitin sulfate 150g
Calcium hydrogen phosphate (in calcium) 500g
Lactose 2000g
Ethanol is an amount of
Micropowder silica gel 10g
Make 1000 bags
Preparation method is with embodiment 7.
Replace calcium hydrogen phosphate with the nanometer calcium hydrogen phosphate in the foregoing description, prescription and preparation method are identical.
The tablet formulation of [embodiment 9] glucosamine hydrochloride, chondroitin sulfate and nanometer calcium hydrogen phosphate and preparation method are with embodiment 1.
The chewable tablet prescription of [embodiment 10] glucosamine hydrochloride, chondroitin sulfate and nanometer calcium hydrogen phosphate and preparation method are with embodiment 5.
The dispersible tablet prescription of [embodiment 11] glucosamine hydrochloride, chondroitin sulfate and nanometer calcium hydrogen phosphate and preparation method are with embodiment 6.
The mix suspension grain agent prescription of [embodiment 12] glucosamine hydrochloride, chondroitin sulfate and nanometer calcium hydrogen phosphate and preparation method are with embodiment 7.
Claims (8)
1, a kind of pharmaceutical composition of preventing and treating senile osteoarthritis is characterized in that: this pharmaceutical composition comprises glucosamine hydrochloride, chondroitin sulfate and calcium hydrogen phosphate and the acceptable accessories as active component.
2, the pharmaceutical composition of the senile osteoarthritis of control according to claim 1 is characterized in that: the consumption of described glucosamine hydrochloride is that the consumption of 125-1500mg, chondroitin sulfate is that the consumption of 100-1200mg, calcium hydrogen phosphate is counted 40-500mg with calcium.
3, the pharmaceutical composition of the senile osteoarthritis of control according to claim 2 is characterized in that: the consumption of described glucosamine hydrochloride is that the consumption of 150-750mg, chondroitin sulfate is that the consumption of 150-600mg, calcium hydrogen phosphate is counted 150-300mg with calcium.
4, the pharmaceutical composition of the senile osteoarthritis of control according to claim 3 is characterized in that: the consumption of described glucosamine hydrochloride is that the consumption of 375mg, chondroitin sulfate is that the consumption of 300mg, calcium hydrogen phosphate is counted 200mg with calcium.
5, according to the pharmaceutical composition of any senile osteoarthritis of described control of claim 1-4, it is characterized in that: described calcium hydrogen phosphate is the nanometer calcium hydrogen phosphate.
6, according to the pharmaceutical composition of any senile osteoarthritis of described control of claim 1-4, it is characterized in that: described acceptable accessories is filler, disintegrating agent, binding agent, lubricant.
7, the pharmaceutical composition of the senile osteoarthritis of control according to claim 6, it is characterized in that: described filler is mannitol or lactose, described disintegrating agent is one or both in crospolyvinylpyrrolidone or the cross-linking sodium carboxymethyl cellulose, described binding agent is ethanol or hydroxypropyl emthylcellulose, and described lubricant is one or more in micropowder silica gel, magnesium stearate, Pulvis Talci, the PEG400.
8, the pharmaceutical composition of the senile osteoarthritis of control according to claim 1 is characterized in that: described pharmaceutical composition is tablet, dispersant, chewable tablet, effervescent tablet, capsule or mix suspension grain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710105249A CN100596278C (en) | 2007-05-24 | 2007-05-24 | Medicinal composition for preventing and treating senile osteoarthropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710105249A CN100596278C (en) | 2007-05-24 | 2007-05-24 | Medicinal composition for preventing and treating senile osteoarthropathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101057862A true CN101057862A (en) | 2007-10-24 |
| CN100596278C CN100596278C (en) | 2010-03-31 |
Family
ID=38864265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710105249A Expired - Fee Related CN100596278C (en) | 2007-05-24 | 2007-05-24 | Medicinal composition for preventing and treating senile osteoarthropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100596278C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904866A (en) * | 2010-09-07 | 2010-12-08 | 许阳 | Medicinal composition for treating osteoporosis and preparation method thereof |
| CN101690728B (en) * | 2009-09-23 | 2011-09-21 | 沈阳亿灵医药科技有限公司 | Composition for treating osteoarthritis |
| CN102342954A (en) * | 2010-08-04 | 2012-02-08 | 张义兴 | Oral liquid composition for improving osteoarthritis and preparation method thereof |
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN101647805B (en) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof |
| CN102626225A (en) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | Health food having functions of bone density increasing and joint protecting, and preparation method thereof |
| CN104873534A (en) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | Glucosamine chondroitin tablets and preparation technology thereof |
| WO2021179319A1 (en) * | 2020-03-13 | 2021-09-16 | 南京汉欣医药科技有限公司 | Composition containing hydrolyzed chondroitin sulfate for preventing and treating osteoarthropathy |
| CN114288349A (en) * | 2022-01-05 | 2022-04-08 | 盖茨汉普(武汉)植物应用研究有限公司 | MitoQ glucosamine soft capsule preparation formula and preparation process |
| US11572421B2 (en) | 2019-11-01 | 2023-02-07 | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof |
-
2007
- 2007-05-24 CN CN200710105249A patent/CN100596278C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647805B (en) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof |
| CN101690728B (en) * | 2009-09-23 | 2011-09-21 | 沈阳亿灵医药科技有限公司 | Composition for treating osteoarthritis |
| CN102342954A (en) * | 2010-08-04 | 2012-02-08 | 张义兴 | Oral liquid composition for improving osteoarthritis and preparation method thereof |
| CN102342954B (en) * | 2010-08-04 | 2013-05-01 | 张义兴 | Oral liquid composition for improving osteoarthritis and preparation method thereof |
| CN101904866A (en) * | 2010-09-07 | 2010-12-08 | 许阳 | Medicinal composition for treating osteoporosis and preparation method thereof |
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN102626225A (en) * | 2012-04-25 | 2012-08-08 | 广东仙乐制药有限公司 | Health food having functions of bone density increasing and joint protecting, and preparation method thereof |
| CN104873534A (en) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | Glucosamine chondroitin tablets and preparation technology thereof |
| US11572421B2 (en) | 2019-11-01 | 2023-02-07 | Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof |
| WO2021179319A1 (en) * | 2020-03-13 | 2021-09-16 | 南京汉欣医药科技有限公司 | Composition containing hydrolyzed chondroitin sulfate for preventing and treating osteoarthropathy |
| CN114288349A (en) * | 2022-01-05 | 2022-04-08 | 盖茨汉普(武汉)植物应用研究有限公司 | MitoQ glucosamine soft capsule preparation formula and preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100596278C (en) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057862A (en) | Medicinal composition for treating senile osteoarthropathy | |
| US6255295B1 (en) | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue | |
| CN87105828A (en) | The quick-acting compositionss of sulindac or sodium sulindac and alkali | |
| CN101559218A (en) | Composition with function of increasing bone density | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| JP5689458B2 (en) | Methods for stabilizing dietary supplements containing glucosamine | |
| CA2870813C (en) | Dietary fiber compositions for the treatment of metabolic disease | |
| CN1357328A (en) | Medicine preparation and its production process | |
| CN1250227C (en) | Aminoglucose hydrochloride medicinal composition | |
| CN1316978C (en) | Compound glucosamine sulfate dispersible tablet formulation and its preparation method | |
| WO2001032188A1 (en) | Compositions of orally administered nutritional supplements to repair articular cartilage | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN1679941A (en) | Compound preparation consisting of taurine and medicines for hepatopathy and production thereof | |
| US7214666B1 (en) | Composition of orally administered nutritional supplements to repair articular cartilage | |
| US20130065823A1 (en) | Supplement for Strengthening the Muscles of a Human | |
| CN1709502A (en) | Composite joint-improving oral liquid | |
| CN1907269A (en) | Aminoglucose composite effervescent preparation | |
| CN1314400C (en) | Solid preparation taken through oral cavity of compound MEthoxyphEnaminE and preparation method | |
| CN104523804A (en) | Capsule for increasing bone density and preparation method of capsule | |
| CN101066252A (en) | Aminoglucose calcium tablet and its prepn process | |
| CN1810242A (en) | Slow-released vincamine capsule and its prepn process | |
| CN1679608A (en) | Compound preparation of inosine, triphosphoadenosine and vitamin C and use thereof | |
| CN1679616A (en) | Compound tablet for treating gastritis and preparation thereof | |
| CN1231175A (en) | Fluoracyl melatonin and composition and preparation thereof | |
| CN1268327C (en) | Brufen arginine pseudoephedrine hydrochloride compound formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WUHU SINOCAN BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG YIXING Effective date: 20101227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200031 ROOM 106, BUILDING 5, BIYU GARDEN, ERLI STREET, HEFEI CITY, ANHUI PROVINCE TO: 241003 NEW AND HIGH TECHNOLOGY INDUSTRIAL DEVELOPMENT AREA, WUHU CITY, ANHUI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101227 Address after: 241003 hi tech Industrial Development Zone, Anhui, Wuhu Patentee after: Biological Pharmaceutical Co., Ltd. Wuhu Zhongjia Address before: 200031 Anhui city of Hefei Province in the two Street Garden Building 5, room 106, Bi rain Patentee before: Zhang Yixing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100331 Termination date: 20150524 |
|
| EXPY | Termination of patent right or utility model |